CP-461

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Malignant Melanoma

Conditions

Malignant Melanoma

Trial Timeline

Jan 1, 2003 → Dec 1, 2004

NCT ID

NCT00060710

About CP-461

CP-461 is a phase 2 stage product being developed by Astellas Pharma for Malignant Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00060710. Target conditions include Malignant Melanoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00060710	Phase 2	Terminated	Jan 1, 2003	Dec 1, 2004	Malignant Melanoma
NCT00042055	Phase 2	Completed	Jul 1, 2002	Sep 1, 2003	Crohn's Disease
NCT00036257	Phase 1	Completed	Mar 1, 2002	Apr 1, 2003	Chronic Lymphocytic Leukemia
NCT00036075	Phase 2	Completed	Aug 1, 2001	Dec 1, 2005	Prostate Cancer
NCT00036036	Phase 2	Completed	Jul 1, 2001	Jul 1, 2003	Renal Cell Carcinoma

Competing Products

20 competing products in Malignant Melanoma

See all competitors

Product	Company	Stage	Hype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + Bevacizumab	CSPC Pharmaceutical Group Limited	Phase 1/2	40
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	52
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	33
Patritumab Deruxtecan	Daiichi Sankyo	Phase 1/2	41
Tivantinib + FOLFOX	Daiichi Sankyo	Phase 1/2	41
DS-1123	Daiichi Sankyo	Phase 1	33
DS-8201a	Daiichi Sankyo	Phase 1	33
DS-5573a	Daiichi Sankyo	Phase 1	33
DS-6051b	Daiichi Sankyo	Phase 1	33
U3-1565	Daiichi Sankyo	Phase 1	33
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue Medications	Daiichi Sankyo	Phase 1/2	41
DS-3201b + DS-3201b	Daiichi Sankyo	Phase 1	33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kg	Daiichi Sankyo	Phase 1	33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin	Astellas Pharma	Phase 1/2	41
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	52
enfortumab vedotin	Astellas Pharma	Phase 1	33
LNF1901 Monoclonal Antibody Injection	Sun Pharmaceutical	Phase 1	33
Perampanel + Standard of Care	Eisai	Phase 1/2	41
Pembrolizumab + Lenvatinib + Placebo for lenvatinib	Eisai	Phase 3	77
Eribulin Mesylate	Eisai	Phase 1	33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved